AZ AZ
Company Profile ↓Company Overview
AZ (AZ) is a publicly traded company listed on with a market capitalization of $264.64M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $7.90M (+47.0% YoY); net profit $-37.73M.
- Trailing 12 Months Year-on-year growth — revenue +47.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.46% |
| 1 Year: | 46.97% |
Stock Price Performance
| 1 Year: | -38.97% |
| 6 Months: | -2.27% |
| 3 Months: | -15.43% |
| 1 Month: | +0.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -5.5% CAGR over 5 years.
- Trading 40.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 1.55M | 1.16M | 1.55M | 3.65M | 3.32M |
| Cost of Revenue | - | 967.00K | 890.00K | 1.02M | 3.93M | 3.18M |
| Gross Profit | - | 580.00K | 270.00K | 526.00K | -282.00K | 139.00K |
| Operating Expenses | - | 7.16M | 7.07M | 4.64M | 18.69M | 8.17M |
| Operating Income | - | -6.58M | -6.80M | -4.11M | -18.97M | -8.03M |
| EBITDA | - | -5.58M | -10.81M | -1.12M | -18.01M | -7.57M |
| Interest Expense | -139.00K | 39.00K | 223.00K | 116.00K | - | 414.00K |
| Pretax Income | - | -5.76M | -11.15M | -1.40M | -17.74M | -8.28M |
| Tax Provision | - | 0 | 0 | 0 | - | - |
| Net Income | - | -6.42M | -12.52M | -1.30M | -17.49M | -8.07M |
| Diluted EPS | - | -0.19 | -0.35 | -0.07 | - | -0.18 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 9.35M | 9.21M | 5.38M | 7.90M |
| Cost of Revenue | - | 7.52M | 7.96M | 3.49M | 6.81M |
| Gross Profit | - | 1.83M | 1.25M | 1.89M | 1.09M |
| Operating Expenses | - | 19.31M | 20.59M | 14.44M | 37.55M |
| Operating Income | - | -17.48M | -19.34M | -12.55M | -36.46M |
| EBITDA | - | -17.46M | -18.19M | -17.93M | -35.06M |
| Interest Expense | - | 97.00K | 62.00K | 47.00K | 185.00K |
| Pretax Income | - | -18.35M | -19.28M | -18.84M | -36.06M |
| Tax Provision | 142.00K | 0 | 0 | - | - |
| Net Income | - | -16.56M | -16.06M | -17.00M | -37.73M |
| Diluted EPS | - | -1.50 | -1.16 | -0.80 | -1.03 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.69M | 8.52M | 18.88M | 85.16M |
| Current Assets | - | 6.94M | 4.73M | 17.13M | 79.41M |
| Cash & Equivalents | - | 2.62M | 2.27M | 13.53M | 13.53M |
| Inventory | - | 375.00K | 250.00K | 796.00K | 3.89M |
| Receivables | - | 1.37M | 1.48M | 2.02M | 3.03M |
| Total Liabilities | - | 9.80M | 10.83M | 12.03M | 8.74M |
| Current Liabilities | - | 6.24M | 5.63M | 11.54M | 6.95M |
| Long Term Debt | - | 341.00K | 228.00K | 108.00K | 29.00K |
| Total Debt | - | 2.63M | 1.99M | 1.39M | 2.62M |
| Total Equity | - | 5.29M | 2.49M | 13.91M | 77.97M |
| Shares Outstanding | - | 12.38M | 15.36M | 29.59M | 43.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.43M | -11.39M | -11.71M | -22.91M |
| Investing Cash Flow | - | -1.56M | -320.00K | -269.00K | -57.02M |
| Financing Cash Flow | - | 6.10M | 10.89M | 22.81M | 81.31M |
| Capital Expenditure | - | -727.00K | -174.00K | -140.00K | -1.09M |
| Free Cash Flow | - | -10.16M | -11.56M | -11.85M | -24.00M |
| Net Change in Cash | - | -4.89M | -814.00K | 10.95M | 1.38M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 19.6% | 13.6% | 35.1% | 13.8% |
| Operating Margin % | - | -186.9% | -209.9% | -233.4% | -461.4% |
| Net Margin % | - | -177.1% | -174.3% | -316.1% | -477.6% |
| ROE % | - | -313.2% | -645.3% | -122.2% | -48.4% |
| ROCE % | - | -270.7% | -669.7% | -171.0% | -46.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AZ
AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed' - CNBC
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNVS1KQnBkQTRhaDZnVk5GVWQ0ajd6dzBGUmVhVHBfeXUtcEF1bURTV0JaanVLQzRrcU50Qm95X2NGcV95NDVWV0g1ZXlQaEtLdGtzVU5UbmlsY19SWGZPcjAyQVdlSUxJSVZjaVRadnFvRWhYTk5BaXFMYkpVVFo1aXI3T3ZKZXZYQ2fSAY…
A2Z Cust2Mate's Q2 results call starts at 5 p.m. Aug. 12 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNMFVkM3NrQnRLeUhUbDdZRlEtR2JXN1k0RVBPOEZ5enNzeW1acGJXTWotUlRjSXBBSWNScmNLQXhqOTkwOEN1NFpKOGl3bmRfZXJ3OHpCMm91dHE3V04zTUpWaGhYdU5tczAtT2NqN0JwMVJaenBkU3BBNjladDdDYy1jX3lLaGJXakhMc0…
‘The Odyssey’ drives IMAX stock to new peak - Latest news from Azerbaijan
<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE5aQTJLSXlHSUV3dzh6a2U0cmhIMVdsSWxkYTIyQ0ZDZlAtSkh5b3VHTFRLZnFBVnVobndSOVpaVnQ0YktNdlVNMG1qS09wV0tNTWt6YWZyVXZYV1VDTnFqYXlUS1NSRmF0NWNTNkhaZw?oc=5" target="_blank">‘The Odyssey’ dri…
Phoenix pool retailer's stock plunges 45% amid bankruptcy reports - The Business Journals
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQTEdLTEQ5bkROcUZfSUVrcDJmZlcyZUx6QjhZWm5KYVFZbWxqWllUdmNlSktNZlZfQmJLcF9ueVJYSlRHODdJT2NmU2dNalhvR0JBY1c1Z2tZTjZpQkY3MXZTQ21JYnZRcWVlU3JhS3Ftc2pYSno5OFdBampvNDVXbzd6LU5YbDY4cW9HRn…
A2Z Cust2Mate Solutions Corp. (AZ) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNb3FtV3Y1ZVlnY2pVa3duMlBQVzlrdGdjWnJST2hpQkg2aWVKX0pwQ1lXVzV0dF80U3lqUWoxZ3dnN2RPc05yalRwUDhtTjAyZzRkUlVTVjNBTVMyRHY3Vml2VXdJcE4zbDk4UW0ycFJlcjZPX0pjRlVFMHJ6aVoxT0gtcUNMemFMVkhWam…
AZ - Finviz
<a href="https://news.google.com/rss/articles/CBMiQ0FVX3lxTE9HQTRzby1ZNjVZSG1sRndBWEU3bS1MZzhBVmNYdzh4OEdZc1ByQTRNY2RMMmxWemVsQWJ6SUhra3M2bmM?oc=5" target="_blank">AZ</a> <font color="#6f6f6f">Finviz</font>…
AZ — Frequently Asked Questions
What is the current share price of AZ?
As of 2026-08-05 17:25 PDT, AZ trades at $6.03 on NASDAQ/NYSE. Its 52-week range is $5.12 to $10.10.
What is the market capitalisation of AZ?
AZ has a market capitalisation of $264.64M on NASDAQ/NYSE.
What is the P/E ratio of AZ?
AZ trades at a trailing price-to-earnings (P/E) ratio of -5.85. Its price-to-book (P/B) ratio is 3.39.
What is the return on equity (ROE) of AZ?
AZ has a return on equity (ROE) of -48.40%. Its return on capital employed (ROCE) is -46.61%.
Is AZ a good stock to buy?
This page provides a data-driven analysis of AZ, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.